[Selective serotonin reuptake inhibitors (SSRIs) in pregnancy]. 2006

R Tango, and P Berney, and P Schulz
Unité de psychopharmacologie clinique, Service de pharmacologie et toxicologie cliniques, HUG, Genève.

Recent studies suggest several problems associated with selective serotonin reuptake inhibitors (SSRIs) when administered during pregnancy. During organogenesis, paroxetine (Deroxat, Paxil, or generics) was associated with a significantly increased risk of major congenital malformations. Such an increase had already been reported with clomipramine (Anafranil), a tricyclic antidepressant. After the time of organogenesis, SSRIs have also been associated to risks. Of these, the more frequent is neonatal toxicity, while pulmonary hypertension in the newborn is likely to be the more severe. These newly discovered side effects arouse questions about the treatment of depression during pregnancy.

UI MeSH Term Description Entries
D011247 Pregnancy The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH. Gestation,Pregnancies
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000014 Abnormalities, Drug-Induced Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. Drug-Induced Abnormalities,Abnormalities, Drug Induced,Abnormality, Drug-Induced,Drug Induced Abnormalities,Drug-Induced Abnormality
D017367 Selective Serotonin Reuptake Inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. 5-HT Uptake Inhibitor,5-HT Uptake Inhibitors,5-Hydroxytryptamine Uptake Inhibitor,5-Hydroxytryptamine Uptake Inhibitors,SSRIs,Selective Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitor,Serotonin Reuptake Inhibitors,Serotonin Uptake Inhibitor,Serotonin Uptake Inhibitors,Inhibitors, 5-HT Uptake,Inhibitors, 5-Hydroxytryptamine Uptake,Inhibitors, Serotonin Reuptake,Inhibitors, Serotonin Uptake,Reuptake Inhibitors, Serotonin,Uptake Inhibitors, 5-HT,Uptake Inhibitors, 5-Hydroxytryptamine,Uptake Inhibitors, Serotonin,Inhibitor, 5-HT Uptake,Inhibitor, 5-Hydroxytryptamine Uptake,Inhibitor, Serotonin Reuptake,Inhibitor, Serotonin Uptake,Reuptake Inhibitor, Serotonin,Uptake Inhibitor, 5-HT,Uptake Inhibitor, 5-Hydroxytryptamine,Uptake Inhibitor, Serotonin

Related Publications

R Tango, and P Berney, and P Schulz
January 2008, MCN. The American journal of maternal child nursing,
R Tango, and P Berney, and P Schulz
October 2018, Current neurology and neuroscience reports,
R Tango, and P Berney, and P Schulz
November 2012, The Cochrane database of systematic reviews,
R Tango, and P Berney, and P Schulz
November 2019, The Cochrane database of systematic reviews,
R Tango, and P Berney, and P Schulz
November 2021, The Cochrane database of systematic reviews,
R Tango, and P Berney, and P Schulz
October 2016, Current osteoporosis reports,
R Tango, and P Berney, and P Schulz
March 1994, International clinical psychopharmacology,
R Tango, and P Berney, and P Schulz
January 2006, Journal of child and adolescent psychopharmacology,
R Tango, and P Berney, and P Schulz
March 2005, Bioorganic & medicinal chemistry letters,
R Tango, and P Berney, and P Schulz
August 2009, Nursing,
Copied contents to your clipboard!